Study shows experimental drug cuts stroke risk

Aug 30, 2009 By MARIA CHENG , AP Medical Writer

(AP) -- An experimental drug reduces the stroke risk in patients with irregular heartbeats by more than three times, compared with the popular drug warfarin - but possibly at a cost, according to new research released Sunday.

Patients taking the new drug dabigatran etexilate, made by German pharmaceutical Boehringer Ingelheim, also were slightly more likely to have heart attacks or stomach pain, according to the research presented at the European Society of Cardiology meeting in Barcelona.

Patients with irregular heartbeats are up to five times more likely to have a stroke than healthy people.

About one-sixth of all strokes occur in patients with irregular heartbeats who also have other risk factors such as smoking or obesity. In the United States, there are about 2 million people with such a condition.

Until now most such patients have been given warfarin, which has been around since the 1950s and has side effects including bleeding risks and requires lifestyle changes such as dietary restrictions.

Doctors hope the new drug can help improve treatment for patients, who must be monitored continuously if they are put on warfarin and avoid alcohol and foods such as spinach and cranberries.

The new research on dabigatran - which has not yet been approved in the United States but is sold as Pradaxa in 40 countries to prevent blood clots - was compiled after doctors monitored more than 18,000 patients with irregular heartbeats, or atrial fibrillation, worldwide for about two years starting in 2005. The patients took either dabigatran or warfarin, at varying doses.

On warfarin a patient's risk of stroke drops dramatically to about 0.38 percent per year, according to the study, also published online in the . Warfarin has invited complications, however, because it is difficult to dose and may be confusing for patients to take, doctors have said.

On dabigatran, that risk is slashed even further to about 0.10 percent per year, the study says.

"It is certainly a big step forward," said Dr. Fausto Pinto, director of the Cardiovascular Institute at the University of Lisbon, Portugal, and program chairman of the European Society of Cardiology.

Dabigatran "probably will replace warfarin," as it is easier for both doctors and patients to use, said Pinto, who was not involved in the study.

Last year, the market for anti-clotting drugs was about $13.6 billion globally.

Getting approval for dabigatran could take years after Boehringer Ingelheim submits data to regulatory agencies.

Dr. Clyde Yancy, medical director of the Baylor Heart and Vascular Institute in Dallas and president of the American Heart Association, said more information was needed on why dabigatran appeared to slightly increase the number of heart attacks, but that overall the data were encouraging.

"Patients have wanted something easier to take for their atrial fibrillation for years, and this may be it," Yancy said. "That's why this may be a game-changer."

----

On the Net:

http://www.escardio.org
http://www.nejm.org

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Added benefit of vedolizumab is not proven

add to favorites email to friend print save as pdf

Related Stories

Study: Plavix plus aspirin helps prevent strokes

Mar 31, 2009

(AP) -- Taking the blood thinner Plavix along with aspirin helped prevent strokes and heart attacks in people with a common heartbeat abnormality that puts them at high risk of these problems, doctors reported Tuesday.

FDA clears Eli Lilly's blood thinner Effient

Jul 10, 2009

(AP) -- The Food and Drug Administration on Friday approved a highly anticipated blood thinner from Eli Lilly, though the drug must carry the agency's sternest warning because of its bleeding risks.

Study: Some heart patients undoing drug benefits

Mar 12, 2009

(AP) -- European heart patients are taking more medication than ever before to lower their blood pressure and cholesterol, but bad habits such as overeating and smoking are undermining the drugs, a new study says. Despite ...

Risk said associated with Eli Lilly drug

Nov 05, 2007

A new experimental drug from Indianapolis-based Eli Lilly and Co. has been found to have a risk of major bleeding, sometimes even death, a report says.

Study: Cholesterol drug lowers blood clot risk

Mar 29, 2009

(AP) -- Statin drugs, taken by millions of Americans to lower cholesterol and prevent heart disease, also can cut the risk of developing dangerous blood clots that can lodge in the legs or lungs, a major study suggests.

Recommended for you

Added benefit of vedolizumab is not proven

17 hours ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0